Literature DB >> 31471628

Clinical relevance of circadian melatonin release in relapsing-remitting multiple sclerosis.

Simone Kern1,2, Michael Geiger3,4, Madlen Paucke3,4, Alina Kästner3,4, Katja Akgün3,4, Tjalf Ziemssen3,4.   

Abstract

A growing body of evidence indicates the role of melatonin (MT) in the pathogenesis of multiple sclerosis (MS): It modulates immune function, alleviates oxidative stress and it is linked to seasonality of MS relapse. This report addresses the potential clinical relevance of circadian MT rhythms in relapsing-remitting MS (RRMS) patients. The study sample comprised of fifty-five RRMS patients and fifty age- and sex-matched healthy control (HC) subjects. Circadian salivary MT was measured non-invasively at 12 time points over day in participants' home environment. 6-Hydroxy-melatoninsulfate (MT sulfate) concentration in night-time urine was assessed as an estimate for nocturnal MT. Ratings for neurological disability, health-related quality of life (HrQoL), fatigue, depressive symptoms and sleep patterns were additionally obtained. There was no evidence for an overall disturbed MT rhythm in RRMS patients. However, lower MT levels within the first hour after awakening were associated with longer disease duration. MT levels only correlated moderately with neurological disability. Sleep disruptions were more common in patients than in controls and were associated with lower nocturnal MT sulfate levels. MT also correlated moderately with fatigue and HrQoL. We did not find evidence for a generally disturbed circadian MT rhythm in RRMS patients but longer disease duration was associated with significantly lower MT levels. Moreover, MT correlated with a series of clinical features. The exact nature of this relationship remains unclear and future studies are needed in order to determine whether MT could serve as a potential therapeutic target in MS. KEY MESSAGES: Melatonin acts as a free radical scavenger and modulates immune function. In multiple sclerosis, low melatonin levels were associated with acute exacerbations. Melatonin levels are not generally disturbed in multiple sclerosis patients. But lower levels are associated with disease duration and clinical aspects. Salivary melatonin after awakening might serve as a good measure of melatonin.

Entities:  

Keywords:  Circadian rhythms; Fatigue; Melatonin; Multiple sclerosis; Neurological disability

Mesh:

Substances:

Year:  2019        PMID: 31471628     DOI: 10.1007/s00109-019-01821-w

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  38 in total

1.  Two formulas for computation of the area under the curve represent measures of total hormone concentration versus time-dependent change.

Authors:  Jens C Pruessner; Clemens Kirschbaum; Gunther Meinlschmid; Dirk H Hellhammer
Journal:  Psychoneuroendocrinology       Date:  2003-10       Impact factor: 4.905

2.  Disruption of melatonin circadian rhythm production is related to multiple sclerosis severity: A preliminary study.

Authors:  Alfredo Damasceno; Adriel Santos Moraes; Alessandro Farias; Benito Pereira Damasceno; Leonilda Maria Barbosa dos Santos; Fernando Cendes
Journal:  J Neurol Sci       Date:  2015-04-07       Impact factor: 3.181

Review 3.  The kynurenine pathway in neurodegenerative diseases: mechanistic and therapeutic considerations.

Authors:  Lin Tan; Jin-Tai Yu; Lan Tan
Journal:  J Neurol Sci       Date:  2012-08-29       Impact factor: 3.181

4.  Cerebrospinal fluid kynurenines in multiple sclerosis; relation to disease course and neurocognitive symptoms.

Authors:  Shahin Aeinehband; Philip Brenner; Sara Ståhl; Maria Bhat; Mark D Fidock; Mohsen Khademi; Tomas Olsson; Göran Engberg; Jussi Jokinen; Sophie Erhardt; Fredrik Piehl
Journal:  Brain Behav Immun       Date:  2015-07-17       Impact factor: 7.217

5.  Melatonin enhances interleukin-10 expression and suppresses chemotaxis to inhibit inflammation in situ and reduce the severity of experimental autoimmune encephalomyelitis.

Authors:  Shyi-Jou Chen; Shing-Hwa Huang; Jing-Wun Chen; Kai-Chen Wang; Yung-Rong Yang; Pi-Fang Liu; Gu-Jiun Lin; Huey-Kang Sytwu
Journal:  Int Immunopharmacol       Date:  2015-12-29       Impact factor: 4.932

6.  Relationship of nocturnal melatonin levels to duration and course of multiple sclerosis.

Authors:  R Sandyk; G I Awerbuch
Journal:  Int J Neurosci       Date:  1994-04       Impact factor: 2.292

7.  Plasma and cerebrospinal fluid tryptophan in multiple sclerosis and degenerative diseases.

Authors:  F Monaco; S Fumero; A Mondino; R Mutani
Journal:  J Neurol Neurosurg Psychiatry       Date:  1979-07       Impact factor: 10.154

8.  Time matters - acute stress response and glucocorticoid sensitivity in early multiple sclerosis.

Authors:  Simone Kern; Nicolas Rohleder; Graeme Eisenhofer; Jan Lange; Tjalf Ziemssen
Journal:  Brain Behav Immun       Date:  2014-05-29       Impact factor: 7.217

9.  Measuring the impact of MS on walking ability: the 12-Item MS Walking Scale (MSWS-12).

Authors:  J C Hobart; A Riazi; D L Lamping; R Fitzpatrick; A J Thompson
Journal:  Neurology       Date:  2003-01-14       Impact factor: 9.910

10.  Factors associated with poor sleep quality in patients with multiple sclerosis differ by disease duration.

Authors:  Marianna Vitkova; Zuzana Gdovinova; Jaroslav Rosenberger; Jarmila Szilasiova; Iveta Nagyová; Pavol Mikula; Martina Krokavcova; Johan W Groothoff; Jitse P van Dijk
Journal:  Disabil Health J       Date:  2014-06-07       Impact factor: 2.554

View more
  5 in total

Review 1.  The role of melatonin in Multiple Sclerosis.

Authors:  Charalampos Skarlis; Maria Anagnostouli
Journal:  Neurol Sci       Date:  2019-12-16       Impact factor: 3.307

Review 2.  SARS-CoV-2 infection in multiple sclerosis patients: interaction with treatments, adjuvant therapies, and vaccines against COVID-19.

Authors:  Ana Muñoz-Jurado; Begoña M Escribano; Eduardo Agüera; Javier Caballero-Villarraso; Alberto Galván; Isaac Túnez
Journal:  J Neurol       Date:  2022-07-05       Impact factor: 6.682

Review 3.  Melatonin and multiple sclerosis: antioxidant, anti-inflammatory and immunomodulator mechanism of action.

Authors:  Ana Muñoz-Jurado; Begoña M Escribano; Javier Caballero-Villarraso; Alberto Galván; Eduardo Agüera; Abel Santamaría; Isaac Túnez
Journal:  Inflammopharmacology       Date:  2022-06-05       Impact factor: 5.093

4.  Time to activin on pathogenic T cells.

Authors:  Anna Ebering; Ari Waisman
Journal:  Proc Natl Acad Sci U S A       Date:  2020-05-22       Impact factor: 11.205

Review 5.  Adaptive immunity, chronic inflammation and the clock.

Authors:  Kathryn J Gray; Julie E Gibbs
Journal:  Semin Immunopathol       Date:  2022-03-01       Impact factor: 11.759

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.